National Institutes of Health: Thyroid Diseases trials

The registry lists 45 Thyroid Diseases studies with National Institutes of Health as lead sponsor. 0 are open to participants now and 28 have results posted.

Phase 1 7Phase 2 29Phase 3 1Phase 4 1No phase 12(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Pembrolizumab in Recurrent or Metastatic Medullary Thyroid CancerCompletedNCT03072160Phase 2Results posted
• CUDC-907 Treatment in People With Metastatic and Locally Advanced Thyroid CancerTerminatedNCT03002623Phase 2Results posted
• Total Thyroidectomy With and Without Prophylactic Central Neck Lymph Node Dissection in People With Low-risk Papillary Thyroid CancerTerminatedNCT02408887Phase 2Results posted
• Ponatinib for Advanced Medullary Thyroid CancerTerminatedNCT01838642Phase 2Results posted
• Cabozantinib-S-Malate in Treating Patients With Refractory Thyroid CancerCompletedNCT01811212Phase 2Results posted
• Cabozantinib S-Malate in Treating Younger Patients With Recurrent or Refractory Solid TumorsCompletedNCT01709435Phase 1Results posted
• Sorafenib Tosylate in Treating Younger Patients With Relapsed or Refractory Rhabdomyosarcoma, Wilms Tumor, Liver Cancer, or Thyroid CancerCompletedNCT01502410Phase 2Results posted
• A Phase I/II Trial of Crolibulin (EPC2407) Plus Cisplatin in Adults With Solid Tumors With a Focus on Anaplastic Thyroid Cancer (ATC)CompletedNCT01240590Phase 1/2Results posted
• Intensity-Modulated Radiation Therapy and Paclitaxel With or Without Pazopanib Hydrochloride in Treating Patients With Anaplastic Thyroid CancerCompletedNCT01236547Phase 2Results posted
• Cediranib Maleate With or Without Lenalidomide for the Treatment of Thyroid CancerCompletedNCT01208051Phase 1/2Results posted
• A Phase II Trial of Valproic Acid in Patients With Advanced Thyroid Cancers of Follicular Cell OriginCompletedNCT01182285Phase 2Results posted
• A Targeted Phase I/II Trial of ZD6474 (Vandetanib; ZACTIMA) Plus the Proteasome Inhibitor, Bortezomib (Velcade ), in Adults With Solid Tumors With a Focus on Hereditary or Sporadic, Locally Advanced or Metastatic Medullary Thyroid Cancer (MTC)TerminatedNCT00923247Phase 1/2Results posted
• Aflibercept in Treating Patients With Recurrent and/or Metastatic Thyroid Cancer That Did Not Respond to Radioactive Iodine TherapyCompletedNCT00729157Phase 2Results posted
• Thyroid Hormones Homeostasis and Energy Metabolism Changes During Stimulation of Endogenously Secreted Bile Acids (BAs)CompletedNCT00706381Phase 3Results posted
• Pazopanib Hydrochloride in Treating Patients With Advanced Thyroid CancerCompletedNCT00625846Phase 2Results posted
• Selumetinib in Treating Patients With Papillary Thyroid Cancer That Did Not Respond to Radioactive IodineCompletedNCT00559949Phase 2Results posted
• Vandetanib to Treat Children and Adolescents With Medullary Thyroid CancerCompletedNCT00514046Phase 1/2Results posted
• Sorafenib Tosylate in Treating Patients With Metastatic, Locally Advanced, or Recurrent Medullary Thyroid CancerCompletedNCT00390325Phase 2Results posted
• Sunitinib Malate in Treating Patients With Thyroid Cancer That Did Not Respond to Iodine I 131 and Cannot Be Removed by SurgeryCompletedNCT00381641Phase 2Results posted
• Effect of Lithium Carbonate on Low-Dose Radioiodine Therapy in Early Thyroid CancerCompletedNCT00251316Phase 2Results posted
• Suberoylanilide Hydroxamic Acid in Treating Patients With Metastatic and/or Locally Advanced or Locally Recurrent Thyroid CancerCompletedNCT00134043Phase 2Results posted
• Sorafenib in Treating Patients With Advanced Anaplastic Thyroid CancerTerminatedNCT00126568Phase 2Results posted
• Tanespimycin in Treating Patients With Inoperable Locoregionally Advanced or Metastatic Thyroid CancerCompletedNCT00118248Phase 2Results posted
• Thyroid and Glucose and Energy MetabolismCompletedNCT00106119Phase 2Results posted
• Bortezomib in Treating Patients With Metastatic Thyroid Cancer That Did Not Respond to Radioactive Iodine TherapyCompletedNCT00104871Phase 2Results posted
• Romidepsin in Treating Patients With Recurrent and/or Metastatic Thyroid Cancer That Has Not Responded to Radioactive IodineCompletedNCT00098813Phase 2Results posted
• Decitabine in Treating Patients With Metastatic Papillary Thyroid Cancer or Follicular Thyroid Cancer Unresponsive to Iodine I 131CompletedNCT00085293Phase 2Results posted
• Study of Thyrotropin-Releasing Hormone in Normal Volunteers and in Patients With Thyroid or Pituitary AbnormalitiesCompletedNCT00054756Phase 2Results posted
• Administering Peripheral Blood Lymphocytes Transduced With a Murine T-Cell Receptor Recognizing Human Thyroglobulin to People With Thyroglobulin Expressing Thyroid CancerWithdrawnNCT02390739Phase 1/2
• Metabolic Effects of Synthetic Thyroid Hormone for Thyroid Cancer TreatmentCompletedNCT01441154
• Study of Molecular Pathways in Medullary Thyroid Carcinoma and Correlation of Molecular Data With Clinical Behavior of the MTC in Individuals PatientsCompletedNCT01424878
• Thyroid Cancer Among Chornobyl Clean-up Workers in Ukraine: Pilot StudyTerminatedNCT01265381
• Pharmacogenomic Response to Thyrotropin-Releasing Hormone Stimulation in Healthy Volunteers: The Influence of a Common Type 2 Deiodinase Genetic Polymorphism on Serum T3CompletedNCT00812149
• Metabolism and Thyroid Hormone Changes During Exposure to Cold TemperaturesCompletedNCT00521729Not applicable
• Radiation Exposure and Thyroid Disease in KazakhstanCompletedNCT00480428
• Thyroid Abnormalities Associated With Exposure to Atmospheric Emissions of Radioactive IodineTerminatedNCT00342693
• Studies of Thyroid Abnormalities in Northeastern Kazakhstan Associated With Nuclear Weapons TestingCompletedNCT00341185
• Scientific Protocol for the Study of Thyroid Cancer and Other Thyroid Disease in Ukraine Following the Chernobyl AccidentCompletedNCT00341094
• Scientific Protocol for the Study of Thyroid Cancer and Other Thyroid Disease in Belarus Following the Chernobyl AccidentCompletedNCT00339716
• Sorafenib Tosylate in Treating Patients With Locally Advanced, Metastatic, or Locally Recurrent Thyroid CancerTerminatedNCT00095693Phase 2
• The Effect of Thyroid Hormone on Drug Elimination in Cancer PatientsCompletedNCT00080574Phase 2
• Gefitinib in Treating Patients With Metastatic or Unresectable Head and Neck Cancer or Non-Small Cell Lung CancerCompletedNCT00068497Not applicable
• Mohawk Culture, Behavior, Toxicant Exposure and HealthCompletedNCT00043238
• Interleukin-12 and Trastuzumab in Treating Patients With Cancer That Has High Levels of HER2/NeuCompletedNCT00004074Phase 1
• Study of Radioiodine (131-I) Uptake Following Administration of Thyrogen and Hypothyroid States During Thyroid Hormone Withdrawal.CompletedNCT00001730Phase 4